Introduction {#s1}
============

Gastric cancer is one of the most common neoplasms and causes millions of deaths worldwide each year. This malignancy is one of the main causes of death in many developing countries, especially in China, where it is the cancer with the second highest annual incidence and the third leading cause of cancer-related mortality ([@b1]-[@b4]). Combined treatment, including surgery, perioperative radiotherapy and chemotherapy, has been recommended for the treatment of gastric cancer, and gastric cancer surgery has gone through several stages of development, from D1 lymph node dissection to D2 lymph node dissection, followed by extended D2 lymph node dissection ([@b5]-[@b9]) and finally the standard D2 lymph node dissection which is used at present ([@b10],[@b11]). However, lymph node dissection for gastric cancer is difficult and controversial, and has been identified as one of the important prognostic factors in gastric cancer patients. The application of lymph node dissection for gastric cancer is in accordance with the standard of evidence-based medicine and principles of maximizing survival and minimizing mortality in patients. In the past, American and European surgeons routinely performed D1 or D1 plus lymph node dissection combined with postoperative radiotherapy and chemotherapy ([@b12],[@b13]) to treat gastric cancer due to poor surgical skills and obesity in patients. Nowadays, standard D2 lymph node dissection has become a mainstream surgical technique in Asia, especially in China, Japan and South Korea, and has been accepted gradually by European and American surgeons ([@b14]). According to the 7th edition of the American Joint Committee on Cancer (AJCC) TNM staging system for gastric cancer, the number of positive lymph nodes ([@b15]) is considered to be an important factor influencing gastric cancer staging. Thus, the method for postoperative lymph node retrieval may be a key factor in gastric cancer staging. In this study, we compared the numbers of positive and total lymph nodes and prognosis in gastric cancer patients whose perigastric lymph node retrieval was performed by surgeons and pathologists respectively.

Materials and methods {#s2}
=====================

Data collection {#s2-1}
---------------

Data were derived from Yantai Yuhuangding Hospital, the Affiliated Hospital of Qingdao University. We enrolled 1, 107 patients who had undergone D2 radical lymph node resection for gastric cancer from January 2008 to December 2011. Ultimately, data from 1, 056 cases including 654 males and 402 females were analyzed because 28 cases were lost to follow-up and 23 cases died from non-gastric cancer-related diseases. The median age of these patients was 58 (range, 31-89) years old. All operations were performed by experienced gastrointestinal surgeons.

The patients were divided into two groups according to the specialty of physicians who performed the postoperative perigastric lymph node retrieval: the surgeon group (475 cases) and the pathologist group (581 cases). For patients in the surgeon group, the surgeons sequentially retrieved lymph nodes postoperatively within half an hour according to lymph node station ([*Figure 1*](#Figure1){ref-type="fig"}) and then submitted the lymph node specimens to the Pathology Department for further examination. For patients in the pathologist group, the pathologists retrieved lymph nodes postoperatively. TNM staging was determined according to the Union for International Cancer Control (UICC)/AJCC guidelines (2010, 7th Edition). This research protocol was approved by the Ethics Committee of Yantai Yuhuangding Hospital, the Affiliated Hospital of Qingdao University.

![Steps of lymph node retrieval by surgeons.](cjcr-28-5-511-g001){#Figure1}

Follow-up {#s2-2}
---------

Follow-up was carried out by outpatient review and telephone interviews, including obtaining medical history, performing physical examinations and determining the presence of tumor markers every 3 to 6 months over the first 3 postoperative years, every 6 months during the third, fourth and fifth postoperative years, and every year after 5 postoperative years. Abdominal CT scans or gastric endoscopy examinations were carried out when necessary according to clinical judgement. The follow-up interval was from the operation date until October 2015, and the median follow-up duration was 54 months. The longest time is 94 months, and the shortest time is 1 month.

Statistical analysis {#s2-3}
--------------------

Statistical analysis was performed using IBM SPSS Statistics (Version 19.0; IBM Corp., New York, USA). We compared the differences between two groups using *t*-test, χ^2^ or Fisher\'s exact probability tests. The Kaplan-Meier method was used to calculate the survival rates, and log-rank tests were used to test for survival differences between the two groups. Two-tailed P\<0.05 was considered statistically significant in all tests.

Results {#s3}
=======

General information of patients {#s3-1}
-------------------------------

There were no significant differences in gender, age, family history of gastrointestinal malignant tumors, tumor location, resection margin, type of Lauren classification, degree of differentiation, tumor diameter, TNM stage, or the use of postoperative radiotherapy or chemotherapy between the two groups. Only the digestive tract reconstruction method differed between the two groups (P\>0.05) ([*Table 1*](#Table1){ref-type="table"}).

###### 

Patients\' clinical and pathological characteristics

  Characteristics                                       No. of cases   χ^2^   P       
  ----------------------------------------------------- -------------- ------ ------- -------
  Gender                                                                      3.387   0.066
  Male                                                  321            361            
  Female                                                154            220            
  Age (year)                                                                  0.078   0.780
  ≤60                                                   251            302            
  \>60                                                  224            279            
  Family history of gastrointestinal malignant tumors                         0.089   0.766
  Yes                                                   40             46             
  No                                                    435            535            
  Tumor location                                                              4.944   0.423
  Upper (U)                                             22             38             
  Middle (M)                                            120            142            
  Lower (L)                                             251            288            
  M+L                                                   24             42             
  U+M                                                   22             32             
  U+M+L                                                 36             39             
  Reconstruction method                                                       8.147   0.017
  Billroth I                                            214            215            
  Billroth II                                           172            256            
  Roux-en-Y                                             89             110            
  Resection margin                                                            0.950   0.622
  Proximal                                              21             19             
  Distal                                                365            452            
  Full stomach                                          89             110            
  Type of Lauren classification                                               3.113   0.211
  Intestinal type                                       281            358            
  Diffuse type                                          153            189            
  Mixed type                                            41             34             
  Degree of differentiation                                                   0.468   0.494
  High and middle                                       164            189            
  Low and undifferentiated                              311            392            
  Tumor diameter (cm)                                                         0.975   0.323
  ≤4                                                    342            401            
  \>4                                                   133            180            
  TNM stage                                                                   0.746   0.862
  I                                                     71             99             
  II                                                    108            126            
  III                                                   247            305            
  IV                                                    49             51             
  Postoperative radiotherapy and chemotherapy                                 1.694   0.429
  Radiotherapy and chemotherapy                         79             103            
  Chemotherapy                                          283            359            
  Neither radiotherapy nor chemotherapy                 113            119            

Number of lymph nodes {#s3-2}
---------------------

In all, the data of positive and total lymph nodes in each group are in accord with normal distribution. We compared the number of lymph nodes by *t*-test. As shown in [*Table 2*](#Table2){ref-type="table"}, the numbers of positive and total lymph nodes were significantly higher in the surgeon group than in the pathologist group (P=0.021, P\<0.001, respectively). Further analysis showed that the total number of lymph nodes in stage I patients and the numbers of positive and total lymph nodes in stage II and stage III patients were higher in the surgeon group than in the pathologist group, and these differences were statistically significant (all P\<0.05). The number of positive lymph nodes in stage I patients and the numbers of positive and total lymph nodes in stage IV patients were also higher in the surgeon group than in the pathologist group, however, these differences were not statistically significant (all P\>0.05).

###### 

Comparison of positive and total numbers of lymph nodes between two groups

  Variables   Lymph node number (*x*±*s*)   P            
  ----------- ----------------------------- ------------ ---------
  All                                                    
  Positive    6.53±4.07                     4.09±3.70    0.021
  Total       29.64±9.64                    20.71±8.56   \<0.001
  Stage I                                                
  Positive    0.18±0.35                     0.17±056     0.353
  Total       19.40±9.62                    15.45±8.59   0.011
  Stage II                                               
  Positive    1.38±1.08                     0.87±1.55    0.031
  Total       25.35±10.80                   16.75±8.56   \<0.001
  Stage III                                              
  Positive    8.11±6.91                     6.66±5.12    0.026
  Total       32.34±12.55                   25.45±8.31   \<0.001
  Stage IV                                               
  Positive    9.27±6.64                     8.93±7.12    0.881
  Total       25.08±6.97                    23.82±9.40   0.186

Survival analysis {#s3-3}
-----------------

In all, the 3- and 5-year survival rates of patients in the surgeon group were higher than those in the pathologist group, but the difference was not statistically significant (P=0.168). Further analysis showed that the survival rates of stage II and III patients were significantly higher in the surgeon group than in the pathologist group (P=0.038, P=0.045, respectively). Patients with stage I and IV gastric cancer in the surgeon group also had higher survival rates than those in the pathologist group, but these differences were not statistically significant (P=0.224, P=0.268, respectively) (*[Table 3](#Table3){ref-type="table"},[Figure 2](#Figure2){ref-type="fig"}-[6](#Figure6){ref-type="fig"}*).

###### 

Comparison of survival rates between two groups

  Variables   Overall survival (%)   P      
  ----------- ---------------------- ------ -------
  All                                       0.168
  3-year      62.2                   55.6   
  5-year      52.8                   46.5   
  Stage I                                   0.224
  3-year      93.1                   86.2   
  5-year      87.2                   79.2   
  Stage II                                  0.038
  3-year      82.0                   73.1   
  5-year      69.5                   61.2   
  Stage III                                 0.045
  3-year      49.2                   38.9   
  5-year      36.3                   28.0   
  Stage IV                                  0.268
  3-year      24.0                   9.1    
  5-year      11.2                   8.8    

![Overall survival of all patients (P=0.168). S, surgeon; P, pathologist.](cjcr-28-5-511-g002){#Figure2}

![Overall survival of patients with stage I gastric cancer (P=0.224). S, surgeon; P, pathologist.](cjcr-28-5-511-g003){#Figure3}

![Overall survival of patients with stage II gastric cancer (P=0.038). S, surgeon; P, pathologist.](cjcr-28-5-511-g004){#Figure4}

![Overall survival of patients with stage III gastric cancer (P=0.045). S, surgeon; P, pathologist.](cjcr-28-5-511-g005){#Figure5}

![Overall survival of patients with stage IV gastric cancer (P=0.268). S, surgeon; P, pathologist.](cjcr-28-5-511-g006){#Figure6}

Discussion {#s4}
==========

In most gastric cancer centres, lymph nodes are retrieved by pathologists ([@b16]). However, pathologists always simply report the positive and total numbers of greater and lesser curvature lymph nodes because they are less familiar with gastric lymph node stations. The UICC guidelines recommend that the total number of harvested lymph nodes in gastric cancer patients should be not less than 16, and lymph node retrieval should be considered incomplete if less than 16 lymph nodes are retrieved ([@b17]). But it did not recommend the details of perigastric lymph node retrieval. Radiotherapy and chemotherapy have been recommended to prevent recurrence in patients with less than 16 lymph nodes harvested. However, most gastric cancer surgeons think that those cases with less than 16 lymph nodes harvested occur due to insufficient postoperative gastric lymph node retrieval by pathologists rather than their poor surgical skills. En bloc lymph node dissection is often used in patients with gastric cancer ([@b18]). It is difficult to determine the number of positive and total lymph nodes in each station if surgeons do not retrieve lymph nodes by station. At present, only the total lymph node number and the positive lymph node number are considered in the National Comprehensive Cancer Network (NCCN) staging guidelines; therefore, pathologists may be satisfied when the number of retrieved perigastric lymph nodes is more than 16. In China, Huang *et al*. have advised the number of lymph nodes should be more than 21 in radical total gastrectomy to ensure the standard D2 radical lymph node dissection for gastric cancer ([@b19]).

However, when lymph node retrieval is performed by surgeons, the surgeons may not only divide lymph nodes into stations but also count sectioned lymph nodes as a single lymph node at each station. This methodological change may greatly reduce the workload of pathologists, increase the total number of perigastric lymph nodes and the number of positive perigastric lymph nodes, improve quality control in the surgical treatment of gastric cancer, and promote the implementation of standard D2 radical lymph node dissection for gastric cancer ([@b20],[@b21]). This methodology may also cause the pathological stages of gastric cancer to shift, resulting in patients initially diagnosed with stage II gastric cancer being diagnosed with stage III gastric cancer. In this study, the false negative rate was lower in patients with stage II gastric cancer in the surgeon group; patients shifted from stage II to stage III gastric cancer may accept more radiotherapy and chemotherapy treatment; therefore, this differential diagnosis may improve the survival of patients with stage II gastric cancer. For stage III patients, we hypothesize that the survival may be improved because of improved quality control in the surgical treatment of gastric cancer. Surgeons may improve lymph node dissection by retrieving the lymph nodes, thereby ensuring the implementation of standard D2 radical lymph node dissection. Additionally, the survival of patients in this study was found to be significantly increased, most likely because more positive lymph nodes were harvested.

Conclusions {#s5}
===========

Compared with retrieval performed by pathologists, postoperative perigastric lymph node retrieval performed by surgeons was associated with significant increase in the total lymph node number of stage I patients, the numbers of positive and total lymph nodes of stage II and III patients, and the survival of stage II and stage III gastric cancer patients. And we suggest that postoperative gastric cancer lymph nodes should be retrieved not only by stations but also by surgeons and then submitted to the Department of Pathology for further examination. This method may be helpful not only in accurately staging patients with gastric cancer and facilitating a decision regarding the subsequent use of radiotherapy and chemotherapy treatment but also in improving the survival of patients with gastric cancer significantly.
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